Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOP: 64Cu-SAR-BBN PET in Prostate Cancer
NCT05613842Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- Aug 2022
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 64Cu-SAR-bombesin in prostate cancer (PCa) (2 arms), sponsored by St Vincent's Hospital. Primary endpoint: Diagnostic potential of 64Cu-SAR-BBN PET at 24 months. Started Aug 2022; status: completed.
02
Drugs
64Cu-SAR-bombesin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05613842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05613842.